Matches in SemOpenAlex for { <https://semopenalex.org/work/W2148950010> ?p ?o ?g. }
- W2148950010 endingPage "61.e1" @default.
- W2148950010 startingPage "55" @default.
- W2148950010 abstract "Background & AimsHelicobacter pylori have become resistant to antimicrobial agents, reducing eradication rates. A 10-day sequential regimen that contains levofloxacin was efficient, safe, and cost saving in eradicating H pylori infection in an area with high prevalence of clarithromycin resistance. We performed a noninferiority randomized trial to determine whether a 5-day levofloxacin-containing quadruple concomitant regimen was as safe and effective as the 10-day sequential regimen in eradicating H pylori in previously untreated patients.MethodsWe randomly assigned patients with H pylori infection to groups that were given 5 days of concomitant therapy (esomeprazole 40 mg twice daily, amoxicillin 1 g twice daily, levofloxacin 500 mg twice daily, and tinidazole 500 mg twice daily; n = 90) or 10 days of sequential therapy (esomeprazole 40 mg twice daily, amoxicillin 1g twice daily for 5 days followed by esomeprazole 40 mg twice daily, levofloxacin 500 mg twice daily, and tinidazole 500 mg twice daily for 5 more days; n = 90). Antimicrobial resistance was assessed by the E-test. Efficacy, adverse events, and costs were determined.ResultsIntention-to-treat analysis showed similar eradication rates for concomitant (92.2%; 95% confidence interval [CI], 84.0%–95.8%) and sequential therapies (93.3%; 95% CI, 86.9%–97.3%). Per-protocol eradication results were 96.5% (95% CI, 91%–99%) for concomitant therapy and 95.5% for sequential therapy (95% CI, 89.6%–98.5%). The differences between sequential and concomitant treatments were 1.1% in the intention-to-treat study (95% CI; −7.6% to 9.8%) and −1.0% in the per-protocol analysis (95% CI; −8.0% to 5.9%). The prevalence of antimicrobial resistance and incidence of adverse events were comparable between groups. Concomitant therapy cost $9 less than sequential therapy.ConclusionsFive days of levofloxacin-containing quadruple concomitant therapy is as effective and safe, and less expensive, in eradicating H pylori infection than 10 days of levofloxacin-containing sequential therapy. Helicobacter pylori have become resistant to antimicrobial agents, reducing eradication rates. A 10-day sequential regimen that contains levofloxacin was efficient, safe, and cost saving in eradicating H pylori infection in an area with high prevalence of clarithromycin resistance. We performed a noninferiority randomized trial to determine whether a 5-day levofloxacin-containing quadruple concomitant regimen was as safe and effective as the 10-day sequential regimen in eradicating H pylori in previously untreated patients. We randomly assigned patients with H pylori infection to groups that were given 5 days of concomitant therapy (esomeprazole 40 mg twice daily, amoxicillin 1 g twice daily, levofloxacin 500 mg twice daily, and tinidazole 500 mg twice daily; n = 90) or 10 days of sequential therapy (esomeprazole 40 mg twice daily, amoxicillin 1g twice daily for 5 days followed by esomeprazole 40 mg twice daily, levofloxacin 500 mg twice daily, and tinidazole 500 mg twice daily for 5 more days; n = 90). Antimicrobial resistance was assessed by the E-test. Efficacy, adverse events, and costs were determined. Intention-to-treat analysis showed similar eradication rates for concomitant (92.2%; 95% confidence interval [CI], 84.0%–95.8%) and sequential therapies (93.3%; 95% CI, 86.9%–97.3%). Per-protocol eradication results were 96.5% (95% CI, 91%–99%) for concomitant therapy and 95.5% for sequential therapy (95% CI, 89.6%–98.5%). The differences between sequential and concomitant treatments were 1.1% in the intention-to-treat study (95% CI; −7.6% to 9.8%) and −1.0% in the per-protocol analysis (95% CI; −8.0% to 5.9%). The prevalence of antimicrobial resistance and incidence of adverse events were comparable between groups. Concomitant therapy cost $9 less than sequential therapy. Five days of levofloxacin-containing quadruple concomitant therapy is as effective and safe, and less expensive, in eradicating H pylori infection than 10 days of levofloxacin-containing sequential therapy." @default.
- W2148950010 created "2016-06-24" @default.
- W2148950010 creator A5003775231 @default.
- W2148950010 creator A5004290937 @default.
- W2148950010 creator A5008300089 @default.
- W2148950010 creator A5011410424 @default.
- W2148950010 creator A5014565273 @default.
- W2148950010 creator A5014595345 @default.
- W2148950010 creator A5024213038 @default.
- W2148950010 creator A5028645029 @default.
- W2148950010 creator A5033161677 @default.
- W2148950010 creator A5034481011 @default.
- W2148950010 creator A5044814609 @default.
- W2148950010 creator A5045864473 @default.
- W2148950010 date "2012-07-01" @default.
- W2148950010 modified "2023-09-28" @default.
- W2148950010 title "Efficacy of 5-Day Levofloxacin-Containing Concomitant Therapy in Eradication of Helicobacter pylori Infection" @default.
- W2148950010 cites W1835890027 @default.
- W2148950010 cites W1888936445 @default.
- W2148950010 cites W1920776299 @default.
- W2148950010 cites W1945946649 @default.
- W2148950010 cites W1966243555 @default.
- W2148950010 cites W1984302829 @default.
- W2148950010 cites W1984637828 @default.
- W2148950010 cites W1997115882 @default.
- W2148950010 cites W2007239126 @default.
- W2148950010 cites W2015654059 @default.
- W2148950010 cites W2017178544 @default.
- W2148950010 cites W2034375845 @default.
- W2148950010 cites W2052603050 @default.
- W2148950010 cites W2055557876 @default.
- W2148950010 cites W2058181904 @default.
- W2148950010 cites W2059956455 @default.
- W2148950010 cites W2099267593 @default.
- W2148950010 cites W2101730203 @default.
- W2148950010 cites W2104536029 @default.
- W2148950010 cites W2107138460 @default.
- W2148950010 cites W2108165724 @default.
- W2148950010 cites W2124176837 @default.
- W2148950010 cites W2130429036 @default.
- W2148950010 cites W2130796878 @default.
- W2148950010 cites W2134494293 @default.
- W2148950010 cites W2144757576 @default.
- W2148950010 cites W2145002241 @default.
- W2148950010 cites W2153165213 @default.
- W2148950010 cites W2154994164 @default.
- W2148950010 cites W2165886643 @default.
- W2148950010 cites W2172178933 @default.
- W2148950010 cites W2181628751 @default.
- W2148950010 cites W4385616346 @default.
- W2148950010 doi "https://doi.org/10.1053/j.gastro.2012.03.043" @default.
- W2148950010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22484118" @default.
- W2148950010 hasPublicationYear "2012" @default.
- W2148950010 type Work @default.
- W2148950010 sameAs 2148950010 @default.
- W2148950010 citedByCount "80" @default.
- W2148950010 countsByYear W21489500102012 @default.
- W2148950010 countsByYear W21489500102013 @default.
- W2148950010 countsByYear W21489500102014 @default.
- W2148950010 countsByYear W21489500102015 @default.
- W2148950010 countsByYear W21489500102016 @default.
- W2148950010 countsByYear W21489500102017 @default.
- W2148950010 countsByYear W21489500102018 @default.
- W2148950010 countsByYear W21489500102019 @default.
- W2148950010 countsByYear W21489500102020 @default.
- W2148950010 countsByYear W21489500102021 @default.
- W2148950010 countsByYear W21489500102022 @default.
- W2148950010 countsByYear W21489500102023 @default.
- W2148950010 crossrefType "journal-article" @default.
- W2148950010 hasAuthorship W2148950010A5003775231 @default.
- W2148950010 hasAuthorship W2148950010A5004290937 @default.
- W2148950010 hasAuthorship W2148950010A5008300089 @default.
- W2148950010 hasAuthorship W2148950010A5011410424 @default.
- W2148950010 hasAuthorship W2148950010A5014565273 @default.
- W2148950010 hasAuthorship W2148950010A5014595345 @default.
- W2148950010 hasAuthorship W2148950010A5024213038 @default.
- W2148950010 hasAuthorship W2148950010A5028645029 @default.
- W2148950010 hasAuthorship W2148950010A5033161677 @default.
- W2148950010 hasAuthorship W2148950010A5034481011 @default.
- W2148950010 hasAuthorship W2148950010A5044814609 @default.
- W2148950010 hasAuthorship W2148950010A5045864473 @default.
- W2148950010 hasConcept C126322002 @default.
- W2148950010 hasConcept C141071460 @default.
- W2148950010 hasConcept C168563851 @default.
- W2148950010 hasConcept C197934379 @default.
- W2148950010 hasConcept C202953159 @default.
- W2148950010 hasConcept C2776409635 @default.
- W2148950010 hasConcept C2776962512 @default.
- W2148950010 hasConcept C2777396551 @default.
- W2148950010 hasConcept C2778204628 @default.
- W2148950010 hasConcept C2778375690 @default.
- W2148950010 hasConcept C2779384505 @default.
- W2148950010 hasConcept C2779708577 @default.
- W2148950010 hasConcept C2780626017 @default.
- W2148950010 hasConcept C2781276175 @default.
- W2148950010 hasConcept C2781413609 @default.
- W2148950010 hasConcept C501593827 @default.
- W2148950010 hasConcept C71924100 @default.